3,469 reports of this reaction
2.9% of all SITAGLIPTIN reports
#4 most reported adverse reaction
DRUG INEFFECTIVE is the #4 most commonly reported adverse reaction for SITAGLIPTIN, manufactured by Merck Sharp & Dohme LLC. There are 3,469 FDA adverse event reports linking SITAGLIPTIN to DRUG INEFFECTIVE. This represents approximately 2.9% of all 119,503 adverse event reports for this drug.
SITAGLIPTIN has an overall safety score of 78 out of 100. Patients taking SITAGLIPTIN who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is a less commonly reported adverse event for SITAGLIPTIN, but still significant enough to appear in the safety profile.
In addition to drug ineffective, the following adverse reactions have been reported for SITAGLIPTIN:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 3,469 FDA reports for SITAGLIPTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 2.9% of all adverse event reports for SITAGLIPTIN, making it a notable side effect.
If you experience drug ineffective while taking SITAGLIPTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.